VRs37. Yes these results are not clinical trial hence not technical valid as support for the hypothesis of MSC’s efficacy in relation to ADRS.
I noticed something a few days ago on the net. That I did not post this at the time as it was just more Mt Sinai news. However I think ist become important. It might be the cause of of this MSB announcement.
https://www.trialsitenews.com/mount-sinai-leading-a-clinical-trial-evaluating-allogeneic-stem-cell-therapy-on-covid-19-ards-patients/
This release by the Mt Sinia hospital might have forced MSB hand. In terms of continuous reporting in order to stay within the asx rules.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-472
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.020(1.81%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.12 | $4.898M | 4.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 596693 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 50805 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
0.020 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.12 | 1420559 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| MSB (ASX) Chart |